POSTMARKETING, PROSPECTIVE, MULTICENTRE, SINGLE-ARM STUDY OF SUBJECTS WHO RECEIVE AN INJECTION OF A MEDICAL DEVICE BASED ON HYALURONIC ACID: CLINICAL STUDY REPORT

Nazar Vadzyuk

doi:10.31435/rsglobal_ws/30032024/8127

Nazar Vadzyuk MD, PhD, SI Institute of Traumatology and Orthopaedics, NAMS of Ukraine Medical Centre Ameda LLC

DOI: https://doi.org/10.31435/rsglobal_ws/30032024/8127

Keywords: Hyaluronic Acid, Intra-Articular Injection, Knee Osteoarthritis, Joint Pain

Abstract

Introduction: Viscosupplementation with an intra-articular injection of hyaluronic acid (HA) is widely used around the globe for pain management in patients with osteoarthritis (OA). Safety and clinical outcomes are debated for decades. First, products have been designed for multiinjections (3–5 injections at 1-week intervals); newer products and treatment schemes are developing continuously. Elevated concentration or dose, additional components, and chemical bonds can provide better and prolonged effects of treatment. All these features could give an advantage like single-injection treatment, prolonged time between injections and better pain management. With the use of a single injection one can get advantages such as the reduction of visits to the doctor and less interventions with their associated risks. For this purpose, a benefit/risk profile of the novel HA formulation was investigated. This study contributes to knee osteoarthritis (KOA) treatment.

Methods: Postmarketing, prospective, multicentre, single-arm study of subjects with knee OA grades II to IV according to the Kellgren and Lawrence classification was used who received a single injection of medical HA-based device was performed. The study has been scheduled in the form of Visit 1 (month 0), Visit 2 (month 1), Visit 3 (month 2), Visit 4 (month 3), Visit 5 (month 4), Visit 6 (month 5) and Visit 7 (month 6). The changes in the WOMAC questionnaire have been evaluated upon treatment initiation for up to 6 months. The incidences of adverse events have been recorded throughout the study.

Results: The clinical study was conducted in Ukraine and Poland by 5 clinical sites; 55 persons who met the study inclusion criteria were involved in the investigation. The age of subjects ranged from 36 to 80 years with mean age of 52.02 years. The score of the WOMAC questionnaire findings resulted in the improvement of pain and function after 1, 2, 3, 4, 5, 6 months compared to the population's baseline data (mean reduction from baseline 13.62, 18.31, 22.79, 22.18, 21.25, 21.55 points, respectively (p<0.001)).

Conclusion: This study showed HA's tolerability and safety in a single-injection application for at least 24 weeks, resulting in a promising treatment option for patients with KOA for whom conventional therapy has failed.

References

Kraus, V. B., Blanco, F. J., Englund, M., Karsdal, M. A., & Lohmander, L. S. (2015). Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthritis and Cartilage, 23(8), 1233–1241. https://doi.org/10.1016/j.joca.2015.03.036.

American Academy of Orthopaedic Surgeons Management of Osteoarthritis of the Knee (Non-Arthroplasty) Evidence-Based Clinical Practice Guideline (3rd Edition). https://www.aaos.org/oak3cpg Published August 31, 2021. Accessed February 20, 2024.

Bannuru, R. R., Osani, M. C., Vaysbrot, E. E., Arden, N. K., Bennell, K. L., Bierma-Zeinstra, S. M. A., Kraus, V. B., Lohmander, L. S., Abbott, J. H., Bhandari, M., Blanco, F., Espinosa, R., Haugen, I., Lin, J., Mandl, L. A., Moilanen, E., Nakamura, N., Snyder‐Mackler, L., Trojian, T. H., . . . McAlindon, T. E. (2019). OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and Cartilage, 27(11), 1578–1589. https://doi.org/10.1016/j.joca.2019.06.011.

Nissen, S. E. (2016). Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. The New England Journal of Medicine, 375(26), 2519–2529. https://doi.org/10.1056/nejmoa1611593.

Pereira, T., Jüni, P., Saadat, P., Xing, D., Yao, L., Bobos, P., Agarwal, A., Hincapié, C. A., & Da Costa, B. R. (2022). Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis. The BMJ, e069722. https://doi.org/10.1136/bmj-2022-069722.

Brandt KD, Smith GN Jr, Simon LS. Intraarticular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence? Arthritis Rheum. 2000 Jun;43(6):1192-203. doi: 10.1002/1529-0131(200006)43:6<1192::AID-ANR2>3.0.CO;2-L.

Zhu, K. Y., Acuña, A. J., Samuel, L. T., Grits, D., & Kamath, A. F. (2022). Hyaluronic Acid Injections for Knee Osteoarthritis: Has Utilization Among Medicare Beneficiaries Changed Between 2012 and 2018?. The Journal of bone and joint surgery. American volume, 104(10), e43. https://doi.org/10.2106/JBJS.21.00832.

Miller, L. E., & Block, J. E. (2013). US-Approved Intra-Articular Hyaluronic Acid Injections are Safe and Effective in Patients with Knee Osteoarthritis: Systematic Review and Meta-Analysis of Randomized, Saline-Controlled Trials. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 6, CMAMD.S12743. https://doi.org/10.4137/cmamd.s12743.

World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013 Nov 27;310(20):2191-4. doi: 10.1001/jama.2013.281053. PMID: 24141714.

Kellgren, J., & Lawrence, J. S. (1957). Radiological Assessment of Osteo-Arthrosis. Annals of the Rheumatic Diseases, 16(4), 494–502. https://doi.org/10.1136/ard.16.4.494.